Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
BioMed X
BioMed X
Activities:
Training & Education
Research & Development
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
KBI Biopharma extends contract with a big pharma giant after a successful FDA inspection
The contract has been renewed and extended until at least 2029, and will now include the purchase of two therapeutic products
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
New FAIRY viral assay could 'revolutionise' the response to future pandemics
The assay, which can detect the infectiousness of a virus in a matter of minutes, offers a quicker and cheaper alternative to the standard cell culture approach
New advice from BOLA and Labtex on cleaning and handling of PTFE products after use
The companies share: "Abrasive scouring agents may result in a milkiness of the vessels made of PFA and FEP. You may use all neutral detergents (pH 7). For higher contamination...
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Research & Development
BioMed X Institute and Merck begin second immunology project
Team TDA will join the three ongoing research groups sponsored by Merck, which follow four completed projects
Research & Development
BioMed X and Boehringer Ingelheim initiate brain sensor project
Two projects are already underway between the research partners, including one in immunology and one in neuroscience
Research & Development
BioMed X completes fourth oncology project with Merck
The next project team: “Synthetic Lethality in DNA Repair” (SDR) is led by Dr Özdemirhan Serçin, who was a postdoctoral researcher in the DDC teamv
Research & Development
BioMed X and Janssen R&D announce two research groups
The groups will explore research related to autoimmunity and drug delivery
Research & Development
BioMed X and Merck launch oncology research programme
The key aim of the project will be to generate a comprehensive atlas of extrachromosomal DNA in human cancer tissues
Research & Development
BioMed X and Merck extend research collaboration
The two entered a partnership in 2013 and the resulting research has led to 25 scientific publications
Research & Development
BioMed X begins research project for oral therapeutics delivery
The collaboration with Janssen Research and Development was facilitated by Johnson & Johnson Innovation
Subscribe now